Table 3.
Fraction of KRAS mutation positive cancer samples | Number of NSCLC patients | Histological diagnosis | KRAS mutation distribution over the cancer tissue | |
---|---|---|---|---|
SSC/ADC/ADSCC/LCNEC | Homogeneous | Inhomogeneous | ||
5/5 | 27 | 16/10/0/1 | 27 | 0 |
4/5 | 2 | 0/2/0/0 | 0 | 2 |
3/5 | 1 | 0/0/0/1 | 0 | 1 |
2/5 | 1 | 0/1/0/0 | 0 | 1 |
1/5 | 1 | 0/0/1/0 | 0 | 1 |
Overall | 32 | 16/13/1/2 | 27 | 5 |
Thirty-two of 51 NSCLCs revealed mutated KRAS gene (point mutations at codon 12) in at least one of all five samples harvested at surgery. Inhomogeneous distribution of KRAS point mutation was noted when not all of five analyzed samples of cancer tissue had detectable mutation
NSCLC non-small cell lung cancer, SCC squamous cell carcinoma, ADC adenocarcinoma, ADSCC adenosquamous cell carcinoma, LCNEC large cell neuroendocrine carcinoma